Literature DB >> 2104811

Pregnancy rate and ovarian hyperstimulation after luteal human chorionic gonadotropin in in vitro fertilization stimulated with gonadotropin-releasing hormone analog and menotropins.

A Herman1, R Ron-El, A Golan, A Raziel, Y Soffer, E Caspi.   

Abstract

The value of luteal phase supplementation with human chorionic gonadotropin (hCG) was assessed after a combined protocol of ovarian stimulation, using a long acting gonadotropin releasing hormone analog (GnRH-a) and human menopausal gonadotropins (hMG), in a randomized prospective study of 36 consecutive cycles in an in vitro fertilization (IVF) program. The patients were allocated on the transfer day to either luteal phase supplementation with hCG (Group A, n = 18) or none (Group B, n = 18). Nine patients of Group A conceived as compared with 3 in Group B. Five patients, all in Group A, developed ovarian hyperstimulation syndrome (OHSS) (3 moderate and 2 severe forms). Analysis of the hormonal profiles disclosed similar progesterone (P), estradiol (E2), and E2/P ratio up to the 6th post ovum pick-up day. Then, E2 and mainly P levels decreased only in Group B resulting in a rising E2/P ratio. These findings stress the importance of luteal support in IVF cycles treated with GnRH-a. In light of the increased risk of OHSS among hCG treated patients, further studies are needed to assess the optimal preparation needed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2104811     DOI: 10.1016/s0015-0282(16)53222-1

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  9 in total

Review 1.  The pathogenesis of ovarian hyperstimulation syndrome: a continuing enigma.

Authors:  A Simon; A Revel; A Hurwitz; N Laufer
Journal:  J Assist Reprod Genet       Date:  1998-04       Impact factor: 3.412

Review 2.  Luteal phase support for assisted reproduction cycles.

Authors:  Michelle van der Linden; Karen Buckingham; Cindy Farquhar; Jan A M Kremer; Mostafa Metwally
Journal:  Cochrane Database Syst Rev       Date:  2015-07-07

3.  The significance of 17 beta-estradiol levels in highly responding women during ovulation induction in IVF treatment: its impact and prognostic value with respect to oocyte maturation and treatment outcome.

Authors:  I Ben-Nun; A Shulman; Y Ghetler; M Shilon; H Kaneti; Y Beyth
Journal:  J Assist Reprod Genet       Date:  1993-04       Impact factor: 3.412

4.  A comparative, randomized study of three different progesterone support of the luteal phase following IVF/ET program.

Authors:  P G Artini; A Volpe; S Angioni; M C Galassi; C Battaglia; A R Genazzani
Journal:  J Endocrinol Invest       Date:  1995-01       Impact factor: 4.256

5.  Prospective randomized comparison of human chorionic gonadotropin versus intramuscular progesterone for luteal-phase support in assisted reproduction.

Authors:  E Araujo; L Bernardini; J L Frederick; R H Asch; J P Balmaceda
Journal:  J Assist Reprod Genet       Date:  1994-02       Impact factor: 3.412

6.  Elective cryopreservation of all embryos in women at risk of developing ovarian hyperstimulation syndrome may not prevent the condition but reduces the live birth rate.

Authors:  A O Awonuga; R J Pittrof; J Zaidi; N Dean; H S Jacobs; S L Tan
Journal:  J Assist Reprod Genet       Date:  1996-05       Impact factor: 3.412

7.  Assessment of the luteal phase in stimulated and substituted cycles.

Authors:  H M Fatemi
Journal:  Facts Views Vis Obgyn       Date:  2009

8.  Duration of luteal support (DOLS) with progesterone pessaries to improve the success rates in assisted conception: study protocol for a randomized controlled trial.

Authors:  Rafet Gazvani; Richard Russell; Yasmin Sajjad; Zarko Alfirevic
Journal:  Trials       Date:  2012-07-26       Impact factor: 2.279

9.  A multi-center, randomized, open-label, parallel group study of a natural micronized progesterone vaginal tablet as a luteal support agent in Japanese women undergoing assisted reproductive technology.

Authors:  Toshihiro Fujiwara
Journal:  Reprod Med Biol       Date:  2015-06-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.